Research Progress on the Application of CGM in Patients with Diabetes and Hemodialysis

Int J Med Sci. 2024 Nov 11;21(15):3083-3090. doi: 10.7150/ijms.102727. eCollection 2024.

Abstract

Diabetes mellitus is the main cause of end-stage renal disease (ESKD), and most patients need hemodialysis (HD) treatment after they progress to uremia. Patients with diabetes and HD have obvious blood glucose fluctuation, hyperglycemia and hypoglycemia may both related to the higher mortality. Therefore, maintaining blood glucose stability is the main treatment strategy to improve the prognosis of patients. It is challenging to evaluate the blood glucose control of patients with diabetes and HD. The traditional blood glucose detection methods have certain limitations, they may be affected by many factors in HD patients. The application of continuous glucose monitoring (CGM) system is gradually recognized, CGM can monitor blood glucose real-time, timely, and predictive capabilities, there are fewer factors that are affected blood glucose in HD patients.

Keywords: Blood glucose fluctuation; Continuous Glucose Monitoring; Diabetes Mellitus; Hemodialysis.

Publication types

  • Review

MeSH terms

  • Blood Glucose* / analysis
  • Continuous Glucose Monitoring*
  • Diabetes Mellitus / blood
  • Diabetes Mellitus / therapy
  • Humans
  • Hypoglycemia / blood
  • Hypoglycemia / diagnosis
  • Hypoglycemia / etiology
  • Kidney Failure, Chronic* / blood
  • Kidney Failure, Chronic* / complications
  • Kidney Failure, Chronic* / therapy
  • Renal Dialysis* / adverse effects

Substances

  • Blood Glucose